MetaBiom
Microbiome & Chronic Diseases

Evidence Based Medicine

Covid-19 {40000510}

Record Keys


Definition:
Covid-19
Class:[  ]

Details


Other Terms:[  ]
Initialisation date:
2021-04-19

Meta Information


ICD:[  ]
Category:[  ]
MedDra ID:[  ]
MedDra Level:[  ]

Notes


- There is an unusual microbiomes in hospitalized COVID-19 patients.
- There is a strong connection between gut microbes and COVID-19 severity.
- In addition to the lungs and gut, the SARS-CoV-2 virus has been detected in the liver, kidney, heart, and brain.
- Intestinal bacteria appear to influence the production of this important mucus barrier, which could prevent viruses in the gut from reaching other parts of the body.
- Dysbiome can predispose to leaky gut and it is highly likely that viruses get access to organs other than the lungs and the gut through a leaky gut.
- SARS-CoV-2 altered the gut microbiome by the tenth day of infection; with some of the changes persisting after 26 days.
- There is a drop in bacterial species known to make short-chain fatty acids (SCFAs), which are important molecules that can regulate the immune system.
- SCFAs produced by gut microbes in mouse travel via the bloodstream to other areas of the body, including the lungs, and can protect the from respiratory viruses.
- Some bacteria manufacture a bacteriocin, that blocks the entry of viruses.
- Bacteroidetes trigger intestinal immune cells to release interferons. Interferons are key factors that ramp up the body’s response to viruses and help eliminate cells that are infected.

Shared Notes


  • [1.5
    - Several gut commensals with known immunomodulatory potential such as Faecalibacterium prausnitzii, Eubacterium rectale and bifidobacteria were underrepresented in patients and remained low in samples collected up to 30 days after disease resolution.
  • [1.7
    - A disrupted gut microbiome (gut dysbiosis) can lead to epithelium breakdown and inflammation, which have been shown to increase levels of angiotensin-converting enzyme 2 (ACE2), the target of SARS-CoV-2.
    - Increased gut permeability can lead to pro-inflammatory bacterial products to leak out and circulate systemically, triggering inflammatory cascades.
    - A specific gut microbiota composition may predispose healthy individuals to severe COVID-19 infections; increased levels of pro-inflammatory bacterial species correlated with elevated levels of pro-inflammatory cytokines and increased disease severity.
    - A disrupted gut microbiome may also contribute to increased pro-inflammatory cytokine production (“cytokine storm”), known to worsen severity of SARS-CoV-2 infection.
    - Proteomic and metabolomic profiling has shown progression to severe COVID-19 infection can be predicted both in infected patients and in healthy individuals.
    - Elderly and immunocompromised populations are known to have reduced microbiota diversity. Since many of these vulnerable patients have had worse clinical outcomes for COVID-19, this strengthens the possibility that the gut microbiome is affecting clinical progression.
    - Reduced gut microbiome diversity may therefore be useful as a predictive biomarker of COVID-19 severity.
    Mechanisms underpinning gastrointestinal symptoms are thought to involve ACE2 receptors, which are highly expressed on intestinal epithelial cells , in particular the brush border membrane of small intestinal enterocytes.
    - ACE2 gene expression has been shown to increase with age, potentially accounting for differential susceptibility to more severe disease.
  • [1.6
    - Bacteroidetes trigger intestinal immune cells to release interferons. Interferons are key factors that ramp up the body’s response to viruses and help eliminate cells that are infected.
    - Bacteroidetes have a specific molecule on their cell surface called a glycolipid that causes intestinal immune cells to release antiviral interferons.
  • - Streptomycetes bacteria manufacture a bacteriocin, called duramycin, that blocks the entry of West Nile, dengue, and Ebola viruses into their host cells. Other bacteriocins halt the replication of herpes simplex viruses.
  • [1.4
    - The gut microbiota of moderate and severe Covid-19 patients has: a) lower Firmicutes/Bacteroidetes ratio, b) higher abundance of Proteobacteria; and c) lower abundance of beneficial butyrate-producing bacteria such as Roseburia and Lachnospira genera.
  • [1.8
    - Faecal microbiota transplant (FMT) restores a damaged gut microbiome and may impact on immune responses,3 including in the respiratory system (‘gut–lung axis’); such microbiome-immune signalling may result in lung-epithelial resistance to SARS-CoV-2
    - Patient 1: an 80-year-old man with multiple comorbidities, including prior CDI, was admitted to hospital with pneumonia/sepsis. Following meropenem treatment, pneumonic features resolved, but CDI relapse occurred. Sequential vancomycin treatment and nasojejunal FMT were administered. On the day of FMT, he developed further fever and C-reactive protein (CRP) increased; repeat microbiology cultures were negative, but SARS-CoV-2 PCR was positive. He commenced on remdesivir and convalescent plasma (CP). Unexpectedly, 2 days after FMT, the fever never recurred and his CRP decreased, without further pneumonia exacerbation.

    - Patient 2: a 19-year-old man with ulcerative colitis on immunosuppression was admitted to hospital because of a relapse of CDI. Vancomycin therapy was administered, and symptomatic improvement occurred; colonoscopic FMT was administered to prevent further recurrence. Fifteen hours post-FMT, he developed fever up to 39°C, with CRP and interleukin-6 (IL-6) levels increased; SARS-CoV-2 PCR returned positive. Subsequently, other than two isolated episodes of fever, his temperature did not exceed 36.6°C, and CRP and IL-6 normalised.

Common References